The Lonza CEO said the company is not under any pressure to exit the Capsules and Health Ingredients (CHI) business and is ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

The CDE of China's NMPA has granted BTD to Innovent Biologics' IBI343 as a monotherapy treatment for CLDN18.2-positive PDAC ...

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...

Charles River and Akron Bio have announced the integration of the latter’s CSS liquid cytokines into the former's Cell ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao ...

IMPACT Therapeutics has received the China NMPA marketing authorisation for Senaparib capsules in treating ovarian cancer.

How longitudinal, closed claims data is advancing regulatory, epidemiology, and health economics and outcomes research (HEOR) ...

The radiopharmaceutical developer expanded its reach, acquiring R&D, isotope production, manufacturing, and distribution.

The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...